Using nanotechnology to target glial cells and reduce neuroinflammation in Alzheimer's disease
Nanotechnology for Glial Targeting and Inhibition of Neuroinflammation for Alzheimer’s Disease
This study is exploring a new treatment using tiny particles that can target specific brain cells to help reduce inflammation and clear out harmful proteins in people with Alzheimer's disease, which could help ease symptoms and slow down the progression of the condition.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers, the State Univ of N.j. NIH-funded |
| Lab location | 1 site (Piscataway, United States) |
| Project ID | NIH-10807382 on NIH RePORTER |
What this research studies
This research focuses on developing nanoparticles that specifically target glial cells in the brain to help reduce neuroinflammation associated with Alzheimer's disease. By utilizing synthetic amphiphilic macromolecules, the study aims to enhance the clearance of amyloid-beta, a protein that contributes to the disease's progression. Patients may benefit from a novel treatment approach that not only alleviates symptoms but also potentially slows down the disease's advancement. The research involves laboratory experiments to test the effectiveness of these nanoparticles in blocking inflammatory responses and promoting the clearance of harmful proteins.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease who are experiencing neuroinflammation.
Not a fit: Patients with other forms of dementia or those without a diagnosis of Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that slow the progression of Alzheimer's disease and improve the quality of life for patients.
How similar studies have performed: Previous research has shown promise in using nanotechnology for targeting specific cells in the brain, suggesting that this approach could be effective for Alzheimer's disease as well.
Where this research is happening
Piscataway, United States
- Rutgers, the State Univ of N.j. — Piscataway, United States (Active)
Researchers
- Principal investigator: Moghe, Prabhas V — Rutgers, the State Univ of N.j.
- Study coordinator: Moghe, Prabhas V
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.